Literature DB >> 8364004

Effect of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe congestive heart failure: improvement in hemodynamic and metabolic profile.

N Galie1, A Branzi, G Magnani, G Melandri, I Caldarera, C Rapezzi, C Grattoni, B Magnani.   

Abstract

The hemodynamic and myocardial metabolic effects of enoximone (phosphodiesterase III inhibitor), alone or in combination with metoprolol (beta-adrenergic blocker), were studied in patients with congestive heart failure. Ten patients (New York Heart Association Class III-IV) underwent right heart and coronary sinus catheterization, and parameters were assessed at basal condition, at peak enoximone response (mean intravenous loading dose = 2.2 mg/kg), and after the combination with metoprolol (mean intravenous dose = 8.5 mg). Heart rate tended to increase during enoximone administration (from 102 +/- 16 to 107 +/- 16 min-1, ns) and was reduced during enoximone plus metoprolol (to 88 +/- 15 min-1, p < 0.05 vs. basal). Cardiac index was increased during enoximone (from 2.2 +/- 0.2 to 3.8 +/- 0.5 1/min/m2, p < 0.05) and decreased during enoximone plus metoprolol (to 2.8 +/- 0.5 1/min/m2, p < 0.05 vs. enoximone). Mean pulmonary wedge pressure fell during enoximone and remained reduced during enoximone plus metoprolol (from 27 +/- 9 to 9 +/- 3 and to 13 +/- 4 mmHg, respectively, both p < 0.05). Myocardial oxygen consumption did not change during enoximone (from 27 +/- 8 to 25 +/- 13 ml/min, ns) and was reduced during enoximone plus metoprolol (to 19 +/- 8 ml/min, p < 0.05 vs. basal). Myocardial lactate extraction tended to be lower during enoximone and during enoximone plus metoprolol conditions (from 38 +/- 17% to 26 +/- 20% and to 29 +/- 24%, respectively), but no statistical significance was found. Myocardial efficiency was increased during enoximone and during enoximone plus metoprolol (from 9 +/- 3% to 15 +/- 6% and to 14 +/- 6%, respectively, both p < 0.05). Thus in patients with congestive heart failure enoximone improves hemodynamics and, in most cases, it does not influence energetics. The addition of metoprolol to enoximone reduces heart rate, cardiac index, and myocardial oxygen consumption without any other major changes, producing a more physiologic hemodynamic and metabolic profile.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8364004     DOI: 10.1007/bf00880157

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  46 in total

1.  The measurement of coronary blood flow, oxygen consumption, and efficiency of the left ventricle in man.

Authors:  R J BING; M M HAMMOND
Journal:  Am Heart J       Date:  1949-07       Impact factor: 4.749

2.  Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure.

Authors:  B Andersson; C Blomström-Lundqvist; T Hedner; F Waagstein
Journal:  J Am Coll Cardiol       Date:  1991-10       Impact factor: 24.094

3.  Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance.

Authors:  M H Crawford; K L Richards; M T Sodums; G T Kennedy
Journal:  Am J Cardiol       Date:  1984-04-01       Impact factor: 2.778

4.  Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy.

Authors:  S M Heilbrunn; P Shah; M R Bristow; H A Valantine; R Ginsburg; M B Fowler
Journal:  Circulation       Date:  1989-03       Impact factor: 29.690

5.  Analysis of the inotropic mechanism of enoximone in guinea pig ventricular muscle.

Authors:  S E Jonas; N Mörner; H M Christley; B Wohlfart
Journal:  J Cardiovasc Pharmacol       Date:  1990-09       Impact factor: 3.105

6.  Intravenous and oral MDL 17043 (a new inotrope-vasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients.

Authors:  D Kereiakes; K Chatterjee; W W Parmley; B Atherton; D Curran; A Kereiakes; R Spangenberg
Journal:  J Am Coll Cardiol       Date:  1984-11       Impact factor: 24.094

7.  Myocardial metabolic and hemodynamic effects of a sustained intravenous infusion of nifedipine with and without metoprolol in patients with unstable angina.

Authors:  G Melandri; A Branzi; F Tartagni; D Degli Esposti; S Piazzi; R Motta; A Bargossi; F Fallani; B Magnani
Journal:  Am Heart J       Date:  1991-01       Impact factor: 4.749

8.  Potential deleterious effects of inotropic agents in the therapy of chronic heart failure.

Authors:  A M Katz
Journal:  Circulation       Date:  1986-03       Impact factor: 29.690

9.  Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure.

Authors:  M Packer
Journal:  Am J Cardiol       Date:  1989-01-03       Impact factor: 2.778

10.  Myocardial energetics in dilated cardiomyopathy.

Authors:  L Thierfelder; C H Holubarsch; G Hasenfuss; H J Just
Journal:  Clin Cardiol       Date:  1990-09       Impact factor: 2.882

View more
  4 in total

Review 1.  Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents.

Authors:  S F Shakar; M R Bristow
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

Review 2.  Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5.

Authors:  David Ho; Lin Yan; Kousaku Iwatsubo; Dorothy E Vatner; Stephen F Vatner
Journal:  Heart Fail Rev       Date:  2010-09       Impact factor: 4.214

Review 3.  Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure.

Authors:  Abhishek Jaiswal; Vinh Q Nguyen; Thierry H Le Jemtel; Keith C Ferdinand
Journal:  World J Cardiol       Date:  2016-07-26

Review 4.  Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure.

Authors:  Dianne M Perez
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.